In a research report released Friday, Cantor analyst Caroline Corner reiterated a Buy rating on shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a price …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful 12-month …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) skyrocketed over 93% in pre-market trading up to $34.85 after the pharmaceutical company reported positive data for its second …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with …
Canaccord Genuity analyst Corey Davis came out with a favorable report on Aerie Pharmaceuticals Inc (NASDAQ:AERI) after the FDA allowed ROCKET 2’s primary endpoint …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares shot up 50% on the news that the FDA has agreed to the company’s proposed change in the primary …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) has created a lot of buzz this morning as shares jumped 56% in pre-market trading following news that the …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares shot up 56% to $20.75 in pre-market trading after the FDA agreed to allow Aerie to change the …
